Nyxoah SA Form 6-K Filing Summary

Nyxoah SA has announced two significant updates. Firstly, the company has commercially launched its Genio® system in the Netherlands, with the first implants successfully performed at OLVG West and Zuyderland hospitals. This launch marks a step in Nyxoah's European rollout, offering an alternative treatment for Obstructive Sleep Apnea (OSA) that is patient-centric and externally powered. The Genio system is a leadless and battery-free hypoglossal neurostimulation therapy. Secondly, Nyxoah announced the issuance of the first tranche of convertible bonds, totaling €22.5 million, as part of a larger financing agreement with Heights Capital Management. The company has paid a subscription fee of €1.8 million for this tranche. The bonds carry a 6.5% annual interest rate and have a three-year maturity. Nyxoah also has the option to issue a second tranche of up to €22.5 million, subject to certain conditions. The net proceeds from these financings are intended to support commercialization efforts in the US and other markets, advance clinical data gathering, fund research and development, and for general corporate purposes. The company estimates these financings will extend its cash runway into the third quarter of 2026, or into the first quarter of 2027 if the second tranche is issued.